Fig. 3

Difference in activity of inflammatory and innate antiviral system transcription control pathways in patients with favorable versus unfavorable out6comes after TAVR. TELiS promotor-based bioinformatics analyses were utilized for all genes showing > 25% differential expression between favorable and unfavorable outcome groups. In 6,036 gene transcripts (5257 up-regulated and 778 down-regulated), results indicated increased activity of pre-specified inflammation-related transcription factors NF-κB (mean log ratio 0.39 ± 0.12, p < 0.001 log2 transcription factor binding motif ratio in promotors of up vs. downregulated genes) and AP-1 (mean log ratio 0.42 ± 0.12, p < 0.001) but no significant difference in pre-specified Type I interferon-related transcription factors ISRE (mean log ratio 0.67 ± 0.47, p = NS) or STAT1 (mean log ratio -0.24 ± 0.27, p = NS). AP-1 = Activator Protein 1; IFN = interferon; ISRE = Interferon-stimulated Response Element; NF-κB = Nuclear Factor-κB; TAVR = transcatheter aortic valve replacement; TELiS = Transcription Element Listening System; TFBM = Transcription factor binding motif; STAT1 = Signal Transducer and Activator of Transcription 1